Medicare coverage for Pacific Edge's tests still under review

Medicare coverage determination for Pacific Edge's US lab, remains under review by Novitas, the Medicare Administrative Contractor.

Novitas is currently in discussion with the Centers for Medicare & Medicaid Services (CMS) regarding the local coverage determination (LCD) for genetic testing for oncology.

The ongoing deliberation on the LCD means that Pacific Edge's tests, Cxbladder Triage, Detect, and Monitor, will continue to receive reimbursement from Medicare and Medicare Advantage payers.

This is in line with historical reimbursement rates and subject to medical necessity guidelines.

The company had expected the LCD to be finalized within 365 days of initial posting and the timeframe for finalization is still unknown.

Pacific Edge will provide further updates to shareholders once it gains certainty on the status and timeline of the LCD.